Last updated: July 31, 2026
Evoxac is the former brand name for cevimeline hydrochloride, an oral muscarinic agonist approved to treat dry mouth symptoms in adults with Sjögren's syndrome. Its clinical development is mature, with no identified late-stage program likely to change the product's regulatory or commercial position. The U.S. market is genericized, patent exclusivity has expired, and competition comes primarily from generic cevimeline, pilocarpine, saliva substitutes and non-drug oral-moisturizing products. Future revenue growth depends more on diagnosis and treatment rates for Sjögren's syndrome than on new clinical differentiation.
What is Evoxac and what is cevimeline used for?
Evoxac contains cevimeline hydrochloride, a cholinergic agonist that stimulates muscarinic receptors and increases salivary secretion. The FDA-approved indication is treatment of symptoms of dry mouth in patients with Sjögren's syndrome.
The approved U.S. dose is 30 mg three times daily. The principal safety risks are sweating, nausea, diarrhea, blurred vision, headache and increased urinary frequency. Cevimeline can also produce clinically important cardiovascular, pulmonary and ophthalmic effects because of its parasympathomimetic activity. The FDA label advises caution in patients with asthma, chronic obstructive pulmonary disease, cardiovascular disease, narrow-angle glaucoma and uncontrolled asthma-related bronchial hyperreactivity (U.S. Food and Drug Administration [FDA], 2000).
Evoxac is a symptomatic treatment. It does not modify the autoimmune disease process, restore salivary gland function permanently or prevent Sjögren's syndrome progression.
What clinical trials supported Evoxac approval?
The FDA approval was supported by randomized, double-blind, placebo-controlled clinical studies in patients with Sjögren's syndrome and xerostomia.
Key clinical evidence
| Trial characteristic |
Reported evidence |
| Disease area |
Sjögren's syndrome with dry mouth |
| Study design |
Randomized, double-blind, placebo-controlled |
| Principal doses evaluated |
15 mg and 30 mg, administered three times daily in pivotal development |
| Main endpoint |
Patient-reported improvement in dry-mouth symptoms and salivary flow |
| Efficacy signal |
Greater improvement with cevimeline than placebo, particularly at 30 mg three times daily |
| Common adverse events |
Sweating, nausea, diarrhea, headache and increased urinary frequency |
| Regulatory outcome |
FDA approval for symptomatic treatment of dry mouth in Sjögren's syndrome |
The pivotal studies showed that cevimeline increased salivary flow and improved selected patient-reported measures of dry-mouth severity. The clinical benefit was symptomatic rather than disease modifying. The label also indicates that treatment response is variable and that adverse events can limit adherence.
Cevimeline's evidence base is narrower than the evidence base for general xerostomia therapies because the branded indication is tied to Sjögren's syndrome. Physicians may prescribe it in other settings, but such use is outside the approved indication.
Are there new Evoxac clinical trials or FDA development programs?
No identified late-stage clinical program has materially changed cevimeline's position as of June 2024. The product's development is established, and current clinical activity is more likely to involve Sjögren's syndrome research, salivary-gland biology or symptomatic management than a new Evoxac registration program.
ClinicalTrials.gov lists completed and ongoing studies in Sjögren's syndrome, dry mouth and salivary dysfunction, but the presence of a disease-area trial does not mean that the study is evaluating cevimeline. The relevant commercial question is whether a sponsor is testing a new formulation, combination therapy or disease-modifying treatment that could displace cevimeline. No publicly established program has demonstrated a clear path to replacing generic cevimeline for routine symptomatic treatment.
Clinical-trial outlook
| Development question |
Assessment |
| New pivotal Evoxac trial |
No identified active program with registration-scale significance |
| New indication |
No established FDA expansion |
| New formulation |
No publicly validated formulation program with material market impact |
| Combination therapy |
No approved cevimeline combination |
| Disease modification |
Cevimeline does not modify Sjögren's syndrome |
| Near-term clinical catalyst |
Low |
What is the FDA regulatory status of Evoxac?
The FDA approved Evoxac in 2000 under NDA 20-989 for dry-mouth symptoms associated with Sjögren's syndrome. The original product was marketed by Daiichi Sankyo's U.S. organization, while generic versions are now available from multiple manufacturers.
The FDA-approved product is cevimeline hydrochloride capsules, generally supplied in 30 mg strength. Generic cevimeline products rely on abbreviated new drug applications and must demonstrate pharmaceutical equivalence and bioequivalence to the reference product.
FDA regulatory profile
| Item |
Status |
| Active ingredient |
Cevimeline hydrochloride |
| Original brand |
Evoxac |
| Dosage form |
Oral capsule |
| Common strength |
30 mg |
| Approved indication |
Dry mouth symptoms in adult patients with Sjögren's syndrome |
| Approval pathway |
Original NDA followed by generic ANDAs |
| Current competitive status |
Generic |
| Biologic status |
Not applicable |
| Biosimilar exposure |
None |
What is the Orange Book status of Evoxac?
Evoxac is an approved small-molecule drug, not a biologic. Its original market exclusivity and core patent protection have expired. The commercial pathway is therefore governed primarily by generic substitution and state pharmacy rules rather than by a remaining branded exclusivity period.
The Orange Book should be checked for the current reference-listed drug and any active patents or exclusivity codes because listings can change through regulatory updates. No active, commercially meaningful Evoxac patent barrier is generally recognized in the public record as of June 2024.
Orange Book and exclusivity position
| Protection category |
Status |
| New chemical entity exclusivity |
Expired |
| Core composition patent |
Expired |
| Pediatric exclusivity |
No material current barrier identified |
| Orphan exclusivity |
None identified for the approved indication |
| Active U.S. formulation exclusivity |
None identified |
| Paragraph IV significance |
Low for the original Evoxac product because generic entry has already occurred |
When did Evoxac lose patent exclusivity?
Cevimeline's U.S. patent estate no longer prevents generic entry. The original product has been exposed to generic competition for years, and the relevant exclusivity period ended well before the current market period.
Public patent records associate cevimeline protection with earlier composition, formulation and use claims. Those rights are expired or no longer commercially blocking. Any residual patent covering a narrow formulation or manufacturing process would not restore exclusivity for the standard 30 mg capsule unless it could support enforceable litigation and a product-level injunction, which is not the present market structure.
Patent-estate assessment
| Patent category |
Commercial assessment |
| Active ingredient and chemical composition |
Expired |
| Standard capsule formulation |
No recognized blocking protection |
| Approved Sjögren's use |
Expired or no longer commercially exclusive |
| Manufacturing process |
May exist as narrow technical IP, but does not generally block ordinary generic supply |
| Device or delivery-system patents |
Not relevant to the approved capsule product |
| Patent estate strength |
Weak for lifecycle management; no material moat |
Were there Paragraph IV challenges to Evoxac?
Paragraph IV litigation was relevant during the original generic-entry period. A generic applicant could challenge listed patents by asserting that the patents were invalid, unenforceable or would not be infringed. That process has already produced the current genericized market.
There is no current Paragraph IV event with the commercial significance of a first generic launch. The key reason is that multiple generic products are already marketed. Any later filing would compete in an established generic market rather than unlock a protected branded franchise.
What patent litigation and settlement agreements affect Evoxac?
No active, market-defining patent litigation involving the original Evoxac franchise has been identified as of June 2024. Earlier generic-entry disputes, if any, no longer determine market access in the same way as they would before the first generic launch.
No current settlement agreement appears to preserve meaningful branded exclusivity for Evoxac. The commercial landscape is consistent with a product that has moved from branded patent protection to ordinary generic competition.
How many patents cover Evoxac?
The number of historical patents associated with cevimeline depends on the search scope. A comprehensive search may identify composition, intermediates, formulations, therapeutic uses and manufacturing claims. That count is not the same as the number of active, enforceable patents that can block commercial entry.
For business purposes, the more relevant conclusion is:
- Historical cevimeline-related patents exist.
- Core product protection has expired.
- No active patent estate is known to protect the standard generic 30 mg capsule in a way that supports a branded market monopoly.
- Process patents, if active in a particular jurisdiction, would generally affect manufacturing routes rather than the entire product market.
How does Evoxac compare with Salagen and other dry-mouth treatments?
The principal prescription comparison is pilocarpine, marketed in the United States as Salagen. Both drugs are oral muscarinic agonists used to increase salivary secretion, but they differ in labeling, dosing, tolerability and physician familiarity.
| Product |
Active ingredient |
Main U.S. use |
Typical dosing pattern |
Competitive position |
| Evoxac/generic cevimeline |
Cevimeline |
Dry mouth in Sjögren's syndrome |
30 mg three times daily |
Generic, low brand power |
| Salagen/generic pilocarpine |
Pilocarpine |
Dry mouth in Sjögren's syndrome; radiation-related xerostomia |
Often four times daily, depending on indication |
Generic, established alternative |
| Artificial saliva products |
Various |
Symptomatic relief |
As needed |
OTC and fragmented |
| Oral moisturizers and gels |
Various |
Short-duration relief |
As needed |
Nonprescription substitutes |
| Emerging secretagogues |
Various |
Development-stage |
Program-specific |
Potential future competition |
Cevimeline may be preferred when a patient responds better to its dosing profile or tolerability. Pilocarpine has broader familiarity and an additional radiation-related xerostomia indication. Neither product has strong patent-based differentiation in the U.S. generic market.
What is the market size and forecast for Evoxac?
Public market reports generally estimate the broader cevimeline market rather than sales attributable specifically to the discontinued Evoxac brand. Reported estimates vary substantially because analysts use different geographic scopes, prescription datasets, wholesale-versus-retail definitions and treatment assumptions.
A practical forecast should separate the branded product from the active ingredient:
- Evoxac branded revenue is structurally limited because generic substitution is established.
- Cevimeline active-ingredient revenue is more durable but remains a niche prescription market.
- Market growth is tied to Sjögren's syndrome diagnosis, specialist prescribing and generic pricing.
- Unit growth can coexist with flat or declining dollar revenue because generic prices erode.
Five-year commercial projection
| Scenario, 2024-2029 |
Prescription volume |
Net price |
Revenue direction |
Main driver |
| Base case |
Low single-digit annual growth |
Declines modestly |
Flat to low single-digit growth |
More diagnosis offset by generic erosion |
| Upside case |
Mid-single-digit annual growth |
Stable |
Mid-single-digit growth |
Higher Sjögren's diagnosis and treatment rates |
| Downside case |
Flat or declining |
Declines materially |
Mid- to high-single-digit decline |
Substitution by pilocarpine, OTC products and supply pressure |
The branded Evoxac opportunity is limited. A company evaluating the asset should model generic cevimeline volume, not historical brand sales. The strongest commercial opportunities are likely to involve differentiated formulations, adherence improvements, combination products or distribution efficiency rather than relaunching the original capsule under a premium brand.
What generic entry risks exist for Evoxac?
Generic entry is already the dominant risk, not a future event. The main risks are:
- Price erosion from multiple ANDA holders.
- Pharmacy substitution away from the branded product.
- Limited prescriber incentive to specify brand-only treatment.
- Supply interruptions because small generic markets may have few reliable manufacturers.
- Competition from pilocarpine and nonprescription products.
- Low patient persistence caused by sweating, gastrointestinal adverse events and frequent dosing.
A new entrant could still face manufacturing and regulatory barriers. Cevimeline requires controlled API sourcing, validated production, quality-system compliance and consistent supply. These are operational barriers rather than patent barriers.
What manufacturing and intellectual-property barriers affect cevimeline?
The main barriers are technical and commercial:
- Qualified cevimeline hydrochloride API supply.
- Stability of the finished capsule.
- Bioequivalence against the reference product.
- Compliance with FDA current good manufacturing practice requirements.
- Reliable production at a market price that supports a small-volume generic.
- Regulatory maintenance for ANDA supplements and manufacturing-site changes.
A manufacturing-process patent could constrain a particular synthetic route, but an alternative noninfringing route may remain available. The absence of a strong product patent reduces litigation risk while increasing price competition.
Which companies are challenging or competing with Evoxac?
The competitive set includes generic cevimeline manufacturers, generic pilocarpine manufacturers and OTC oral-care companies. Generic suppliers can change over time because ANDA approvals, commercial launches and product discontinuations are not equivalent events.
The most important competitive comparison is therefore not brand versus brand. It is:
- Generic cevimeline versus generic pilocarpine on prescription volume.
- Prescription secretagogues versus OTC saliva substitutes on treatment persistence.
- Established products versus future Sjögren's syndrome therapies that address inflammation or glandular damage.
No biosimilar risk applies because cevimeline is a small molecule. The relevant substitution risk is generic and therapeutic substitution.
What is the likely generic launch scenario?
For the United States, the generic-launch scenario has already occurred. Further entrants would probably produce incremental price pressure rather than a step-change in access.
Geographic outlook
| Market |
Commercial position |
| United States |
Genericized; no meaningful brand exclusivity |
| Europe |
Availability and naming vary by country; local reimbursement is decisive |
| Japan |
Regulatory and commercial treatment may differ from the U.S. market |
| Emerging markets |
Access depends on registration, API supply and Sjögren's diagnosis |
| Global |
Niche market with fragmented distribution |
How strong is the Evoxac patent estate?
The Evoxac patent estate is weak from a current commercial-protection perspective. The core molecule and approved capsule have no meaningful remaining exclusivity in the United States. The asset may retain value as a low-cost generic product, but it has limited value as a patent-protected lifecycle franchise.
Key Takeaways
- Evoxac is the former brand for cevimeline hydrochloride.
- FDA approval covers symptomatic treatment of dry mouth in adult patients with Sjögren's syndrome.
- The approved dose is 30 mg three times daily.
- The clinical evidence is mature, with no identified late-stage Evoxac program likely to change the product's market position.
- Core patent and regulatory exclusivity have expired.
- Generic cevimeline and pilocarpine are the principal prescription competitors.
- No biosimilar risk applies.
- Current commercial value lies in generic supply, manufacturing efficiency and potential formulation differentiation.
- Revenue is likely to remain niche, with unit growth offset by generic price erosion.
- The branded Evoxac opportunity is materially smaller than the broader cevimeline active-ingredient opportunity.
FAQs
Is Evoxac still available in the United States?
Cevimeline is available in the United States through generic products. Availability of the original Evoxac brand may vary by wholesaler, pharmacy and manufacturer commercialization status.
Is cevimeline stronger than pilocarpine for Sjögren's syndrome?
Neither drug has a universal efficacy advantage. Both increase salivary secretion, and treatment choice usually depends on response, adverse effects, dosing frequency, contraindications and payer coverage.
Can a company obtain new patents on cevimeline?
A company could pursue patents on a genuinely novel formulation, delivery system, manufacturing process or treatment method. A new patent would need to satisfy novelty, nonobviousness and other applicable requirements and would not automatically restore exclusivity for the standard capsule.
Does cevimeline treat Sjögren's syndrome itself?
No. Cevimeline treats the symptom of dry mouth by stimulating salivary secretion. It does not treat the underlying autoimmune disease or prevent glandular damage.
What is the main investment risk for a cevimeline generic?
The main risk is limited market size combined with generic price competition. Additional risks include API supply, manufacturing reliability, product discontinuation and competition from pilocarpine or nonprescription oral-moisturizing products.
References
-
U.S. Food and Drug Administration. (2000). Evoxac (cevimeline hydrochloride) prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. National Library of Medicine. (2024). ClinicalTrials.gov: Studies related to Sjögren's syndrome, xerostomia and salivary dysfunction. National Institutes of Health.
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. FDA.
-
U.S. Food and Drug Administration. (2024). Inactive ingredient database and abbreviated new drug application resources. FDA.
